MA54061A - Dérivés d'arylsulfonylpyrolecarboxamide utilisés en tant qu'activateurs de canal potassique kv3 - Google Patents
Dérivés d'arylsulfonylpyrolecarboxamide utilisés en tant qu'activateurs de canal potassique kv3Info
- Publication number
- MA54061A MA54061A MA054061A MA54061A MA54061A MA 54061 A MA54061 A MA 54061A MA 054061 A MA054061 A MA 054061A MA 54061 A MA54061 A MA 54061A MA 54061 A MA54061 A MA 54061A
- Authority
- MA
- Morocco
- Prior art keywords
- arylsulfonylpyrolecarboxamide
- potassium channel
- derivatives used
- channel activators
- activators
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Biomedical Technology (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Psychology (AREA)
- Pain & Pain Management (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pyridine Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DKPA201800787 | 2018-10-30 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA54061A true MA54061A (fr) | 2021-12-15 |
Family
ID=70327875
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA054061A MA54061A (fr) | 2018-10-30 | 2019-10-30 | Dérivés d'arylsulfonylpyrolecarboxamide utilisés en tant qu'activateurs de canal potassique kv3 |
Country Status (23)
| Country | Link |
|---|---|
| US (1) | US20200131156A1 (fr) |
| EP (1) | EP3873891A1 (fr) |
| JP (1) | JP2022509416A (fr) |
| KR (1) | KR20210086661A (fr) |
| CN (1) | CN113056461A (fr) |
| AR (1) | AR116898A1 (fr) |
| AU (1) | AU2019373367A1 (fr) |
| BR (1) | BR112020013011A2 (fr) |
| CA (1) | CA3116273A1 (fr) |
| CL (1) | CL2021001123A1 (fr) |
| CO (1) | CO2021005579A2 (fr) |
| CR (1) | CR20210285A (fr) |
| DO (1) | DOP2021000081A (fr) |
| EA (1) | EA202190899A1 (fr) |
| EC (1) | ECSP21038534A (fr) |
| IL (1) | IL282639A (fr) |
| JO (1) | JOP20210091A1 (fr) |
| MA (1) | MA54061A (fr) |
| MX (1) | MX2021004935A (fr) |
| PE (1) | PE20211975A1 (fr) |
| SG (1) | SG11202104348XA (fr) |
| TW (1) | TW202031645A (fr) |
| WO (1) | WO2020089262A1 (fr) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2023017263A1 (fr) | 2021-08-10 | 2023-02-16 | Autifony Therapeutics Limited | Modulateurs des canaux potassiques |
| WO2024121552A1 (fr) | 2022-12-06 | 2024-06-13 | Autifony Therapeutics Limited | Composés pour le traitement de troubles du système nerveux central |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20100179203A1 (en) * | 2007-07-04 | 2010-07-15 | Antonio Nardi | Novel pyrazole derivatives useful as potassium channel modulators |
| TW201028421A (en) * | 2009-01-15 | 2010-08-01 | Abbott Lab | Novel benzenesulfonamides as calcium channel blockers |
| WO2011073276A1 (fr) * | 2009-12-16 | 2011-06-23 | Evotec Ag | Dérivés d'arylsulfonamides de benzoxazine en tant que modulateurs de kv.1.3 |
| WO2011073269A1 (fr) * | 2009-12-16 | 2011-06-23 | Evotec Ag | Dérivés d'arylsulfonamides de pipéridine utilisés en tant que modulateurs de kv.1.3 |
| US9290485B2 (en) * | 2010-08-04 | 2016-03-22 | Novartis Ag | N-((6-amino-pyridin-3-yl)methyl)-heteroaryl-carboxamides |
| FR2967674B1 (fr) * | 2010-11-23 | 2012-12-14 | Pf Medicament | Derives d'heteroarylsulfonamides, leur preparation et leur application en therapeutique humaine |
| WO2013120104A2 (fr) * | 2012-02-10 | 2013-08-15 | Constellation Pharmaceuticals | Modulateurs d'enzymes de modification par méthylation, leurs compositions et utilisations |
| US9422252B2 (en) * | 2012-05-22 | 2016-08-23 | Autifony Therapeutics Limited | Triazoles as Kv3 inhibitors |
| GB201521751D0 (en) * | 2015-12-10 | 2016-01-27 | Autifony Therapeutics Ltd | Novel uses |
| GB201522179D0 (en) | 2015-12-16 | 2016-01-27 | Autifony Therapeutics Ltd | Novel compounds |
| GB201613163D0 (en) | 2016-07-29 | 2016-09-14 | Autifony Therapeutics Ltd | Novel compounds |
-
2019
- 2019-10-29 AR ARP190103138A patent/AR116898A1/es unknown
- 2019-10-29 US US16/667,563 patent/US20200131156A1/en not_active Abandoned
- 2019-10-29 TW TW108139051A patent/TW202031645A/zh unknown
- 2019-10-30 CA CA3116273A patent/CA3116273A1/fr not_active Abandoned
- 2019-10-30 KR KR1020217015490A patent/KR20210086661A/ko unknown
- 2019-10-30 EP EP19798210.1A patent/EP3873891A1/fr not_active Withdrawn
- 2019-10-30 AU AU2019373367A patent/AU2019373367A1/en not_active Abandoned
- 2019-10-30 MX MX2021004935A patent/MX2021004935A/es unknown
- 2019-10-30 SG SG11202104348XA patent/SG11202104348XA/en unknown
- 2019-10-30 MA MA054061A patent/MA54061A/fr unknown
- 2019-10-30 JP JP2021547926A patent/JP2022509416A/ja active Pending
- 2019-10-30 BR BR112020013011-7A patent/BR112020013011A2/pt not_active Application Discontinuation
- 2019-10-30 CN CN201980071046.3A patent/CN113056461A/zh active Pending
- 2019-10-30 EA EA202190899A patent/EA202190899A1/ru unknown
- 2019-10-30 CR CR20210285A patent/CR20210285A/es unknown
- 2019-10-30 PE PE2021000636A patent/PE20211975A1/es unknown
- 2019-10-30 JO JOP/2021/0091A patent/JOP20210091A1/ar unknown
- 2019-10-30 WO PCT/EP2019/079587 patent/WO2020089262A1/fr active Application Filing
-
2021
- 2021-04-26 IL IL282639A patent/IL282639A/en unknown
- 2021-04-28 CO CONC2021/0005579A patent/CO2021005579A2/es unknown
- 2021-04-29 DO DO2021000081A patent/DOP2021000081A/es unknown
- 2021-04-29 CL CL2021001123A patent/CL2021001123A1/es unknown
- 2021-05-28 EC ECSENADI202138534A patent/ECSP21038534A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP3873891A1 (fr) | 2021-09-08 |
| ECSP21038534A (es) | 2021-06-30 |
| WO2020089262A1 (fr) | 2020-05-07 |
| CA3116273A1 (fr) | 2020-05-07 |
| PE20211975A1 (es) | 2021-10-05 |
| JOP20210091A1 (ar) | 2023-01-30 |
| TW202031645A (zh) | 2020-09-01 |
| SG11202104348XA (en) | 2021-05-28 |
| CN113056461A (zh) | 2021-06-29 |
| IL282639A (en) | 2021-06-30 |
| CO2021005579A2 (es) | 2021-05-10 |
| AR116898A1 (es) | 2021-06-23 |
| KR20210086661A (ko) | 2021-07-08 |
| DOP2021000081A (es) | 2021-07-30 |
| CR20210285A (es) | 2021-09-16 |
| AU2019373367A1 (en) | 2021-05-27 |
| JP2022509416A (ja) | 2022-01-20 |
| CL2021001123A1 (es) | 2021-10-22 |
| EA202190899A1 (ru) | 2021-08-19 |
| MX2021004935A (es) | 2021-06-08 |
| BR112020013011A2 (pt) | 2021-05-04 |
| US20200131156A1 (en) | 2020-04-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA54452A (fr) | Dérivés de 2-oxoquinazoline utilisés en tant qu'inhibiteurs de la méthionine adénosyltransférase 2a | |
| MA52486A (fr) | Pyridazinones utilisés en tant qu'inhibiteurs de parp7 | |
| MA56398A (fr) | Composés 2,3-dihydroquinazoline en tant qu'inhibiteurs de nav1.8 | |
| MA47120A (fr) | Dérivés pyridine utilisés en tant qu'immunomodulateurs | |
| MA51610A (fr) | Dérivés d'imidazole fusionnés utilisés en tant qu'inhibiteurs d'il-17 | |
| MA47123A (fr) | Dérivés de benzooxazole en tant qu'mmunomodulateurs | |
| CL2022000698A1 (es) | Compuestos de anillo fusionado. (divisional de solicitud 202101171) | |
| MA49888A (fr) | Composés macrocycliques utilisés en tant qu'inhibiteurs de kinase ros1 | |
| MA49566A (fr) | Carboxamides utilisés en tant qu'inhibiteurs des canaux sodiques | |
| MA45153A (fr) | Dérivés de carbonucléosides substitués utiles en tant qu'agents anticancéreux | |
| MX2018015251A (es) | Derivados de 2-amino-4-(amino sustituido)fenil carbamato fluorinado. | |
| MA52754A (fr) | Composés hétérocycliques tricycliques en tant qu'activateurs de sting | |
| MA44498A (fr) | Dérivés d'indoline substituée utilisés en tant qu'inhibiteurs de la réplication du virus de la dengue | |
| MA45375A (fr) | Composés hétérocycliques utilisés en tant qu'agents antibacteriens | |
| MA53377A (fr) | Composés de pyridin-2-one utiles en tant qu'antagonistes de smarca2 | |
| MA51232A (fr) | Indane-amines utiles en tant qu'antagonistes de pd-l1 | |
| MA48987A (fr) | Dérivés d'indoline substitués utilisés en tant qu'inhibiteurs de réplication du virus de la dengue | |
| MA51431A (fr) | Dérivés d'oxy-fluoropipéridine utilisés en tant qu'inhibiteur de kinase | |
| MA49128A (fr) | Dérivés de pyrimidine utilisés en tant que modulateurs des récepteurs des pge2 | |
| MA51774A (fr) | Dérivés de triazolopyrimidine destinés à être utilisés en tant qu'inhibiteurs de la ghréline o-acyltransférase (goat) | |
| MA51881A (fr) | Dérivés d'alcool utilisés en tant qu'agents d'ouverture du canal potassique kv7 | |
| MA54521A (fr) | Dérivés d'oxopyridine substitués | |
| MA54939A (fr) | Hydroxypyridoxazépines utilisées en tant qu'activateurs de nrf2 | |
| MA49126A (fr) | Dérivés de phényle utilisés en tant que modulateurs des récepteurs des pge2 | |
| MA51133A (fr) | Dérivés de pyrrole utilisés en tant qu'inhibiteurs d'acc |